Initial Statement of Beneficial Ownership (3)
29 Junho 2022 - 5:05PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Garay Arpa |
2. Date of Event Requiring Statement (MM/DD/YYYY)
6/28/2022
|
3. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [MRNA]
|
|
(Last)
(First)
(Middle)
C/O MODERNA, INC., 200 TECHNOLOGY SQUARE |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Commercial Officer / |
|
(Street)
CAMBRIDGE, MA 02139
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) | 6/5/2023 (1) | 6/5/2032 | Common Stock | 34766 | $137.15 | D | |
| Restricted Stock Units | (2) | (2) | Common Stock | 18248 | $0 | D | |
| Explanation of Responses: |
| (1) | 25% of this option will vest and become exercisable on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
| (2) | 25% of the shares subject to this restricted stock unit award will vest on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Garay Arpa
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE, MA 02139 |
|
| Chief Commercial Officer |
|
Signatures
|
| Brian Sandstrom, as Attorney-in-Fact | | 6/29/2022 |
| **Signature of Reporting Person | Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
